List view / Grid view
Dr Fernando Garces, Director of Biotechnology and Innovation at BioMap, discusses the huge potential of AI to deliver successful cell and gene therapy products by optimised design of viral vectors.
For the first time ever, researchers have developed an algorithm to predict age at death and indicate early changes related to disease.
Tune into this podcast to understand why researchers are turning to 3D Organoids and how organoids can be made ready for screening.
Artificial intelligence (AI) and machine learning (ML) have been gaining significant attention lately, primarily in discussions about their responsible utilisation. However, these technologies possess a wide spectrum of practical applications, ranging from predicting natural disasters to addressing social disparities. Now, AI is making its mark in the field of cancer…
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
Rob Scoffin and Matthew Habgood from solutions provider Cresset look to the future of drug discovery and the roles that artificial intelligence and machine learning could play.
Researchers from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an artificial intelligence (AI) system capable of identifying and characterising white and red blood cells within microscopic images of blood samples. This AI algorithm holds the potential to aid medical professionals in diagnosing blood…
Scientists have developed a promising new method to detect cancer at very early stages during routine health screens, paving way for improved treatment and recovery.
Tune in to this episode to hear experts discussing the hot topic that is AI and how AI technology is used in drug discovery, looking specifically at how Biotechs & Pharma are trying to keep up with emerging technology.
This article is the second part of Drug Target Review’s Izzy Wood’s discussion with Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, exploring the role of AI in target discovery, its applications in personalised medicine, and the evolving landscape of pharmaceutical development.
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting…
Cornell University launches $11.3 Million Scientific Artificial Intelligence Centre to unlock the potential of human-AI collaboration in scientific discoveries.
Drug Target Review’s Taylor Mixides interviews Cellarity's CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies.
27 June 2023 | By
In this eBook, uncover the transformative potential of AI/ML in single-cell technologies and gain insights into disease progression.
